CARGO Therapeutics Provides Corporate Update

Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors

Seaport Therapeutics Presents New Meta-Analysis Examining Correlations Between Clinical Trial Design Factors and Placebo Response in Major Depressive Disorder Studies

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences